DOCSLIB.ORG

Hijacking of Host Cellular Functions in Staphylococcus Aureus Pathogenesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hijacking of Host Cellular Functions in Staphylococcus Aureus Pathogenesis DOCTORAL THESIS Hijacking of host cellular functions in Staphylococcus aureus pathogenesis Natalia, Bravo-Santano Award date: 2019 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 06. Oct. 2021 Hijacking of host cellular functions in Staphylococcus aureus pathogenesis by Natalia Bravo-Santano, BSc, MRes A thesis submitted in partial fulfilment of the requirements for the degree of PhD Department of Life Sciences University of Roehampton 2019 A mi familia y a Pablo, por estar siempre ahí Abstract Staphylococcus aureus is a facultative intracellular pathogen that invades and replicates within many types of human cells. S. aureus has shown to rapidly overcome traditional antibiotherapy by developing multidrug antibiotic resistance. Furthermore, intracellular S. aureus is protected from the last resort antibiotics – vancomycin, daptomycin and linezolid – since they are unable to achieve intracellular killing. Therefore, there is an urgent need to develop novel anti-infective therapies against S. aureus. Here, I proposed the exploitation of host-directed approaches as a promising strategy. Specifically, I employed three different approaches to unravel those host molecular factors and/or pathways hijacked by MRSA during intracellular infection. By characterizing the host cell metabolism after MRSA infection, I observed several metabolic changes suggesting a starvation-induced autophagic flux and AMPK phosphorylation levels were also increased in MRSA-infected cells. It was hypothesized that intracellular S. aureus induces autophagy for energy generation and nutrient scavenging. Accordingly, host AMPK-inhibition halted S. aureus intracellular proliferation. I further screened 140 host-directed drugs and found three host-directed tyrosine kinase inhibitors – Ibrutinib, Dasatinib and Crizotinib – that substantially impaired intracellular bacterial survival. Particularly, Ibrutinib increased host cell viability after S. aureus infection via inhibition of intracellular bacterial invasion or proliferation and we confirmed the importance of the host receptor EPHA2 for staphylococcal infection. Lastly, I performed a genome-wide shRNA screen to test the importance of 16,000 host genes and identified several host genes important for intracellular MRSA infection. Specifically, I found that silencing the human gene TRAM2 resulted in a significant reduction of intracellular MRSA. TRAM2 is associated with the endoplasmic reticulum SERCA pumps and accordingly, treatment with the SERCA- inhibitor Thapsigargin halted intracellular MRSA proliferation. In summary, I identified three different host-directed drugs – Dorsomorphin, Ibrutinib and Thapsigargin – that impaired intracellular MRSA infection. These findings serve as an important example of feasibility for identifying host-directed therapeutics to tackle S. aureus host cell infection. i Table of contents Abstract Table of contents List of figures List of tables Acknowledgements Author´s declaration Common abbreviations 1. INTRODUCTION .................................................................................................. 1 1.1. Biology of Staphylococcus aureus.............................................................. 1 1.2. S. aureus infections and epidemiology.................................................... 3 1.2.1. Skin and Soft Tissues Infections (SSTI) .......................................... 3 1.2.2. Infective Endocarditis ..................................................................... 3 1.2.3. Osteomyelitis .................................................................................. 4 1.2.4. Toxic shock syndrome (TSS) .......................................................... 4 1.2.5. Pulmonary infections....................................................................... 5 1.2.6. S. aureus bacteraemia ...................................................................... 6 1.3. Emergence of methicillin-resistant S. aureus (MRSA) ............................ 7 1.3.1. Healthcare-associated vs community-associated MRSA .................. 8 1.4. Pathogenesis of S. aureus infections ..................................................... 10 1.4.1. Surface-associated proteins ........................................................... 11 1.4.1.1. Staphylococcal protein A (SpA) ................................................ 12 1.4.1.2. Fibronectin-binding proteins (FnBPs) ........................................ 13 1.4.1.3. Collagen-binding protein (Cna) ................................................. 14 1.4.1.4. Clumping factors (Clfs) ............................................................. 14 ii 1.4.1.5. Elastin binding protein (EbpS) ................................................... 15 1.4.2. Secreted proteins ........................................................................... 15 1.4.2.1. Superantigens ............................................................................ 16 1.4.2.2. Pore-forming toxins ................................................................... 17 1.5. Regulation of S. aureus virulence factors during infection .................... 20 1.6. Biofilm formation................................................................................. 22 1.7. Intracellular fate of Staphylococcus aureus ........................................... 24 1.7.1. S. aureus internalization into non-phagocytic cells ........................ 25 1.7.2. Intracellular persistence, the role of Small Colony Variants (SCVs) ...................................................................................................... 28 1.7.3. S. aureus phagosomal escape ........................................................ 30 1.7.4. Host-cell death induced by S. aureus ............................................. 31 1.8. Clinical management of S. aureus infections ........................................ 33 1.9. Host-directed approaches, a new perspective ........................................ 35 1.10. Justification and aims........................................................................ 43 2. MATERIALS AND METHODS ........................................................................ 46 2.1. Microbiology ....................................................................................... 46 2.1.1. Bacterial strains and culture conditions.......................................... 46 2.1.2. Preparation of bacterial stock ........................................................ 47 2.1.3. Bacterial pre-inoculum preparation for intracellular assays ............ 47 2.1.4. In-vitro growth assays ................................................................... 47 2.2. Cell culture........................................................................................... 50 2.2.1. Cell lines and culture conditions .................................................... 50 2.2.2. Transduction of mammalian cells .................................................. 53 2.2.3. Intracellular infection assays ......................................................... 55 iii 2.2.4. Host cell viability assay ................................................................. 57 2.2.5. Intracellular bacterial estimation.................................................... 58 2.3. Molecular biology ................................................................................ 60 2.3.1. Polymerase chain reaction (PCR) .................................................. 60 2.3.2. Agarose gel electrophoresis ........................................................... 61 2.3.3. DNA extraction ............................................................................. 63 2.3.3.1. Plasmid extraction ..................................................................... 63 2.3.3.2. Bacterial DNA extraction .......................................................... 63 2.3.3.3. Mammalian DNA extraction ...................................................... 64 2.3.4. Molecular cloning and DNA manipulation .................................... 64 2.3.4.1. pCRII-TOPO cloning ................................................................ 65 2.3.4.2. Bacterial transformation ............................................................ 66 2.3.4.3. DNA digestion........................................................................... 66 2.3.4.4. Dephosphorylation of P12-MMP vector..................................... 67 2.3.4.5. DNA ligation ............................................................................. 67 2.3.4.6. Retroviral production and HeLa transduction ............................. 68 2.3.5. ShRNA screening .......................................................................... 70 2.4. Immunoproteomics .............................................................................. 70
Load more

Recommended publications
  • Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications
    Stem Cell Rev and Rep DOI 10.1007/s12015-016-9662-8 Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications Behnam Ahmadian Baghbaderani 1 & Adhikarla Syama2 & Renuka Sivapatham3 & Ying Pei4 & Odity Mukherjee2 & Thomas Fellner1 & Xianmin Zeng3,4 & Mahendra S. Rao5,6 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract We have recently described manufacturing of hu- help determine which set of tests will be most useful in mon- man induced pluripotent stem cells (iPSC) master cell banks itoring the cells and establishing criteria for discarding a line. (MCB) generated by a clinically compliant process using cord blood as a starting material (Baghbaderani et al. in Stem Cell Keywords Induced pluripotent stem cells . Embryonic stem Reports, 5(4), 647–659, 2015). In this manuscript, we de- cells . Manufacturing . cGMP . Consent . Markers scribe the detailed characterization of the two iPSC clones generated using this process, including whole genome se- quencing (WGS), microarray, and comparative genomic hy- Introduction bridization (aCGH) single nucleotide polymorphism (SNP) analysis. We compare their profiles with a proposed calibra- Induced pluripotent stem cells (iPSCs) are akin to embryonic tion material and with a reporter subclone and lines made by a stem cells (ESC) [2] in their developmental potential, but dif- similar process from different donors. We believe that iPSCs fer from ESC in the starting cell used and the requirement of a are likely to be used to make multiple clinical products. We set of proteins to induce pluripotency [3]. Although function- further believe that the lines used as input material will be used ally identical, iPSCs may differ from ESC in subtle ways, at different sites and, given their immortal status, will be used including in their epigenetic profile, exposure to the environ- for many years or even decades.
    [Show full text]
  • Elucidating Biological Roles of Novel Murine Genes in Hearing Impairment in Africa
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 19 September 2019 doi:10.20944/preprints201909.0222.v1 Review Elucidating Biological Roles of Novel Murine Genes in Hearing Impairment in Africa Oluwafemi Gabriel Oluwole,1* Abdoulaye Yal 1,2, Edmond Wonkam1, Noluthando Manyisa1, Jack Morrice1, Gaston K. Mazanda1 and Ambroise Wonkam1* 1Division of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa. 2Department of Neurology, Point G Teaching Hospital, University of Sciences, Techniques and Technology, Bamako, Mali. *Correspondence to: [email protected]; [email protected] Abstract: The prevalence of congenital hearing impairment (HI) is highest in Africa. Estimates evaluated genetic causes to account for 31% of HI cases in Africa, but the identification of associated causative genes mutations have been challenging. In this study, we reviewed the potential roles, in humans, of 38 novel genes identified in a murine study. We gathered information from various genomic annotation databases and performed functional enrichment analysis using online resources i.e. genemania and g.proflier. Results revealed that 27/38 genes are express mostly in the brain, suggesting additional cognitive roles. Indeed, HERC1- R3250X had been associated with intellectual disability in a Moroccan family. A homozygous 216-bp deletion in KLC2 was found in two siblings of Egyptian descent with spastic paraplegia. Up to 27/38 murine genes have link to at least a disease, and the commonest mode of inheritance is autosomal recessive (n=8). Network analysis indicates that 20 other genes have intermediate and biological links to the novel genes, suggesting their possible roles in HI.
    [Show full text]
  • A Regulator of Innate Immune Responses
    (19) TZZ ¥_T (11) EP 2 942 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.11.2015 Bulletin 2015/46 C07K 14/47 (2006.01) A61K 38/00 (2006.01) C12N 15/113 (2010.01) (21) Application number: 15169327.2 (22) Date of filing: 04.08.2009 (84) Designated Contracting States: (72) Inventor: Barber, Glen N. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Palmetto Bay, FL 33157 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (74) Representative: Inspicos A/S Kogle Allé 2 (30) Priority: 04.08.2008 US 129975 P P.O. Box 45 2970 Hørsholm (DK) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 09805473.7 / 2 324 044 This application was filed on 27-05-2015 as a divisional application to the application mentioned (71) Applicant: Barber, Glen N. under INID code 62. Palmetto Bay, FL 33157 (US) (54) STING (STIMULATOR OF INTEFERON GENES), A REGULATOR OF INNATE IMMUNE RESPONSES (57) Novel molecules termed STING which include STING compositions are useful for the treatment of an nucleic acids, polynucleotides, oligonucleotides, pep- immune-related disorder, including treating and prevent- tides, mutants, variants and active fragments thereof, ing infection by modulating immunity. modulate innate and adaptive immunity in a subject. EP 2 942 357 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 942 357 A1 Description RELATED APPLICATIONS 5 [0001] This application claims priority under 35 USC § 119 to U.S.
    [Show full text]
  • Meta-Analysis Identifies Seven Susceptibility Loci Involved in the Atopic March
    ARTICLE Received 20 Jul 2015 | Accepted 6 Oct 2015 | Published 6 Nov 2015 DOI: 10.1038/ncomms9804 OPEN Meta-analysis identifies seven susceptibility loci involved in the atopic march Ingo Marenholz et al.# Eczema often precedes the development of asthma in a disease course called the ‘atopic march’. To unravel the genes underlying this characteristic pattern of allergic disease, we conduct a multi-stage genome-wide association study on infantile eczema followed by childhood asthma in 12 populations including 2,428 cases and 17,034 controls. Here we report two novel loci specific for the combined eczema plus asthma phenotype, which are associated with allergic disease for the first time; rs9357733 located in EFHC1 on chromo- some 6p12.3 (OR 1.27; P ¼ 2.1 Â 10 À 8) and rs993226 between TMTC2 and SLC6A15 on chromosome 12q21.3 (OR 1.58; P ¼ 5.3 Â 10 À 9). Additional susceptibility loci identified at genome-wide significance are FLG (1q21.3), IL4/KIF3A (5q31.1), AP5B1/OVOL1 (11q13.1), C11orf30/LRRC32 (11q13.5) and IKZF3 (17q21). We show that predominantly eczema loci increase the risk for the atopic march. Our findings suggest that eczema may play an important role in the development of asthma after eczema. Correspondence and requests for materials should be addressed to Y.A.L. (email: [email protected]). #A full list of authors and their affiliations appears at the end of the paper. NATURE COMMUNICATIONS | 6:8804 | DOI: 10.1038/ncomms9804 | www.nature.com/naturecommunications 1 & 2015 Macmillan Publishers Limited. All rights reserved. ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9804 he atopic or allergic march describes the sequential located in the same region, we selected the best SNP per 1-Mb progression of different allergic conditions frequently window.
    [Show full text]
  • To Classical/Novel Duck Reovirus Infections in the Spleen Tissue Tao Yun, Jionggang Hua, Weicheng Ye, Zheng Ni, Liu Chen & Cun Zhang*
    www.nature.com/scientificreports OPEN The phosphoproteomic responses of duck (Cairna moschata) to classical/novel duck reovirus infections in the spleen tissue Tao Yun, Jionggang Hua, Weicheng Ye, Zheng Ni, Liu Chen & Cun Zhang* Duck reovirus (DRV) is a fatal member of the genus Orthoreovirus in the family Reoviridae. The disease caused by DRV leads to huge economic losses to the duck industry. Post-translational modifcation is an efcient strategy to enhance the immune responses to virus infection. However, the roles of protein phosphorylation in the responses of ducklings to Classic/Novel DRV (C/NDRV) infections are largely unknown. Using a high-resolution LC–MS/MS integrated to highly sensitive immune-afnity antibody method, phosphoproteomes of Cairna moschata spleen tissues under the C/NDRV infections were analyzed, producing a total of 8,504 phosphorylation sites on 2,853 proteins. After normalization with proteomic data, 392 sites on 288 proteins and 484 sites on 342 proteins were signifcantly changed under the C/NDRV infections, respectively. To characterize the diferentially phosphorylated proteins (DPPs), a systematic bioinformatics analyses including Gene Ontology annotation, domain annotation, subcellular localization, and Kyoto Encyclopedia of Genes and Genomes pathway annotation were performed. Two important serine protease system- related proteins, coagulation factor X and fbrinogen α-chain, were identifed as phosphorylated proteins, suggesting an involvement of blood coagulation under the C/NDRV infections. Furthermore, 16 proteins involving the intracellular signaling pathways of pattern-recognition receptors were identifed as phosphorylated proteins. Changes in the phosphorylation levels of MyD88, NF-κB, RIP1, MDA5 and IRF7 suggested a crucial role of protein phosphorylation in host immune responses of C.
    [Show full text]
  • Dissecting the Genetics of Human Communication
    DISSECTING THE GENETICS OF HUMAN COMMUNICATION: INSIGHTS INTO SPEECH, LANGUAGE, AND READING by HEATHER ASHLEY VOSS-HOYNES Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Epidemiology and Biostatistics CASE WESTERN RESERVE UNIVERSITY January 2017 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We herby approve the dissertation of Heather Ashely Voss-Hoynes Candidate for the degree of Doctor of Philosophy*. Committee Chair Sudha K. Iyengar Committee Member William Bush Committee Member Barbara Lewis Committee Member Catherine Stein Date of Defense July 13, 2016 *We also certify that written approval has been obtained for any proprietary material contained therein Table of Contents List of Tables 3 List of Figures 5 Acknowledgements 7 List of Abbreviations 9 Abstract 10 CHAPTER 1: Introduction and Specific Aims 12 CHAPTER 2: Review of speech sound disorders: epidemiology, quantitative components, and genetics 15 1. Basic Epidemiology 15 2. Endophenotypes of Speech Sound Disorders 17 3. Evidence for Genetic Basis Of Speech Sound Disorders 22 4. Genetic Studies of Speech Sound Disorders 23 5. Limitations of Previous Studies 32 CHAPTER 3: Methods 33 1. Phenotype Data 33 2. Tests For Quantitative Traits 36 4. Analytical Methods 42 CHAPTER 4: Aim I- Genome Wide Association Study 49 1. Introduction 49 2. Methods 49 3. Sample 50 5. Statistical Procedures 53 6. Results 53 8. Discussion 71 CHAPTER 5: Accounting for comorbid conditions 84 1. Introduction 84 2. Methods 86 3. Results 87 4. Discussion 105 CHAPTER 6: Hypothesis driven pathway analysis 111 1. Introduction 111 2. Methods 112 3. Results 116 4.
    [Show full text]
  • Supplementary Table 1 Double Treatment Vs Single Treatment
    Supplementary table 1 Double treatment vs single treatment Probe ID Symbol Gene name P value Fold change TC0500007292.hg.1 NIM1K NIM1 serine/threonine protein kinase 1.05E-04 5.02 HTA2-neg-47424007_st NA NA 3.44E-03 4.11 HTA2-pos-3475282_st NA NA 3.30E-03 3.24 TC0X00007013.hg.1 MPC1L mitochondrial pyruvate carrier 1-like 5.22E-03 3.21 TC0200010447.hg.1 CASP8 caspase 8, apoptosis-related cysteine peptidase 3.54E-03 2.46 TC0400008390.hg.1 LRIT3 leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 1.86E-03 2.41 TC1700011905.hg.1 DNAH17 dynein, axonemal, heavy chain 17 1.81E-04 2.40 TC0600012064.hg.1 GCM1 glial cells missing homolog 1 (Drosophila) 2.81E-03 2.39 TC0100015789.hg.1 POGZ Transcript Identified by AceView, Entrez Gene ID(s) 23126 3.64E-04 2.38 TC1300010039.hg.1 NEK5 NIMA-related kinase 5 3.39E-03 2.36 TC0900008222.hg.1 STX17 syntaxin 17 1.08E-03 2.29 TC1700012355.hg.1 KRBA2 KRAB-A domain containing 2 5.98E-03 2.28 HTA2-neg-47424044_st NA NA 5.94E-03 2.24 HTA2-neg-47424360_st NA NA 2.12E-03 2.22 TC0800010802.hg.1 C8orf89 chromosome 8 open reading frame 89 6.51E-04 2.20 TC1500010745.hg.1 POLR2M polymerase (RNA) II (DNA directed) polypeptide M 5.19E-03 2.20 TC1500007409.hg.1 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 6.48E-03 2.17 TC2200007132.hg.1 RFPL3 ret finger protein-like 3 5.91E-05 2.17 HTA2-neg-47424024_st NA NA 2.45E-03 2.16 TC0200010474.hg.1 KIAA2012 KIAA2012 5.20E-03 2.16 TC1100007216.hg.1 PRRG4 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 7.43E-03 2.15 TC0400012977.hg.1 SH3D19
    [Show full text]
  • Promoterless Transposon Mutagenesis Drives Solid Cancers Via Tumor Suppressor Inactivation
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.17.254565; this version posted August 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation 2 Aziz Aiderus1, Ana M. Contreras-Sandoval1, Amanda L. Meshey1, Justin Y. Newberg1,2, Jerrold M. Ward3, 3 Deborah Swing4, Neal G. Copeland2,3,4, Nancy A. Jenkins2,3,4, Karen M. Mann1,2,3,4,5,6,7, and Michael B. 4 Mann1,2,3,4,6,7,8,9 5 1Department of Molecular Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA 6 2Cancer Research Program, Houston Methodist Research Institute, Houston, Texas, USA 7 3Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), 8 Singapore, Republic of Singapore 9 4Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, 10 Maryland, USA 11 5Departments of Gastrointestinal Oncology & Malignant Hematology, Moffitt Cancer Center & Research 12 Institute, Tampa, FL, USA 13 6Cancer Biology and Evolution Program, Moffitt Cancer Center & Research Institute, Tampa, FL, USA 14 7Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, 15 USA. 16 8Donald A. Adam Melanoma and Skin Cancer Research Center of Excellence, Moffitt Cancer Center, Tampa, 17 FL, USA 18 9Department of Cutaneous Oncology, Moffitt Cancer Center & Research Institute, Tampa, FL, USA 19 These authors contributed equally: Aziz Aiderus, Ana M.
    [Show full text]
  • The Role of Histone Deacetylase 6 Inhibition on Systemic Lupus Erythematosus
    The Role of Histone Deacetylase 6 Inhibition on Systemic Lupus Erythematosus Jingjing Ren Dissertation submitted to the advisory committee members of the Virginia Polytechnic Institute in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Biomedical and Veterinary Sciences Xin M. Luo. Chair Christopher M. Reilly. Co-Chair Kenneth J. Oestreich Thomas E. Cecere August 8, 2019 Blacksburg, VA Keywords: systemic lupus erythematosus, lupus nephritis, germinal center, B cells, plasmacytoid dendritic cells, IFN, T follicular cells. i The Role of Histone Deacetylase 6 Inhibition on Systemic Lupus Erythematosus Jingjing Ren Abstract Systemic lupus erythematosus (SLE) is a chronic multifactorial inflammatory autoimmune disease with heterogeneous clinical manifestations. Among different manifestations, lupus nephritis (LN) remains a major cause of morbidity and mortality. There are few FDA approved treatments for LN. In general, they are non-selective and lead to global immunosuppression with significant side effects including an increased risk of infection. In the past 60 years, only one new drug, belimumab was approved for lupus disease with modest efficacy in clinic and not approved for patients suffering for nephritis. Therefore, it is urgent to develop new treatments to replace or reduce the use of current ones. Histone deacetylase 6 (HDAC6) plays a variety of biologic functions in a number of important molecular pathways in diverse immune cells. Both innate and adaptive immune cells contribute to pathogenesis of lupus. Among those cells, B cells play a central role in pathogenesis of lupus nephritis in an anti-body dependent manner through differentiation into plasma cells (PCs). As a result, HDAC6 inhibitors represent an entirely new class of agents that could have potent effects in SLE.
    [Show full text]
  • Gene Expression Profiles in Acute Myeloid Leukemia with Common Translocations Using SAGE
    Gene expression profiles in acute myeloid leukemia with common translocations using SAGE Sanggyu Lee*†‡, Jianjun Chen*†, Guolin Zhou*†, Run Zhang Shi*, Gerard G. Bouffard§, Masha Kocherginsky¶, Xijin Geʈ, Miao Sun*, Nimanthi Jayathilaka*, Yeong Cheol Kimʈ, Neelmini Emmanuel*, Stefan K. Bohlander**, Mark Minden††, Justin Kline*, Ozden Ozer*, Richard A. Larson*, Michelle M. LeBeau*, Eric D. Green§, Jeffery Trent§‡‡, Theodore Karrison¶, Piu Paul Liu§, San Ming Wangʈ§§, and Janet D. Rowley*§§ Departments of *Medicine and ¶Health Studies, University of Chicago, Chicago, IL 60637; §National Human Genome Research Initiative, National Institutes of Health, Bethesda, MD 20892; ʈENH Research Institute, Northwestern University, Evanston, IL 60208; **Department of Medicine III, Ludwig Maximilians University and GSF-National Research Center for Environmental and Health, Clinical Cooperative Group ‘‘Leukemia,’’ 80539 Munich, Germany; and ††Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada M5G 2M9 Contributed by Janet D. Rowley, November 21, 2005 Identification of the specific cytogenetic abnormality is one of the sex, stage of disease, percentage of blasts in the sample, other critical steps for classification of acute myeloblastic leukemia (AML) chromosomal abnormalities, etc.) as well as for technical rea- which influences the selection of appropriate therapy and provides sons, such as the various platforms and algorithms used in the information about disease prognosis. However at present, the analysis. Moreover
    [Show full text]
  • Transcriptional Network Analysis of Transcriptomic Diversity in Resident Tissue Macrophages and Dendritic Cells in the Mouse Mononuclear Phagocyte System
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.24.002816; this version posted March 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Transcriptional network analysis of transcriptomic diversity in resident tissue macrophages and dendritic cells in the mouse mononuclear phagocyte system. Kim M. Summers*, Stephen J. Bush# and David A. Hume* *Mater Research Institute-University of Queensland, Translational Research Institute, WoolloonGabba, Qld 4012, Australia and #Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK. The three authors contributed eQually to this work. Address for correspondence Professor David Hume Mater Research Institute-University of Queensland Translational Research Institute 37 Kent Street WoolloonGabba, Qld 4102 Australia [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.24.002816; this version posted March 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract The mononuclear phaGocyte system (MPS) is a family of cells includinG proGenitors, circulatinG blood monocytes, resident tissue macrophaGes and dendritic cells (DC) present in every tissue in the body. To test the relationships between markers and transcriptomic diversity in the MPS, we collected from NCBI-GEO >500 Quality RNA-seQ datasets Generated from mouse MPS cells isolated from multiple tissues.
    [Show full text]
  • Genome-Wide Pathway Analysis Implicates Intracellular Transmembrane Protein Transport in Alzheimer Disease
    Journal of Human Genetics (2010) 55, 707–709 & 2010 The Japan Society of Human Genetics All rights reserved 1434-5161/10 $32.00 www.nature.com/jhg SHORT COMMUNICATION Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease Mun-Gwan Hong1, Andrey Alexeyenko1, Jean-Charles Lambert2,3,4, Philippe Amouyel2,3,4 and Jonathan A Prince1 We developed and implemented software for the analysis of genome-wide association studies in the context of biological pathway enrichment and have here applied our algorithm to the study of Alzheimer disease (AD). Using genome-wide association data in a large French population, we observed a highly significant enrichment of genes involved in intracellular protein transmembrane transport, including several mitochondrial proteins and nucleoporins. An intriguing aspect of these findings is the implication that TOMM40, the channel-forming subunit of the translocase of the mitochondrial outer membrane complex, and a gene generally considered to be indiscernible from APOE because of linkage disequilibrium, may itself contribute to Alzheimer pathology. Results provide an indication that protein trafficking, in particular across the nuclear and mitochondrial membranes, may contribute to risk for AD. Journal of Human Genetics (2010) 55, 707–709; doi:10.1038/jhg.2010.92; published online 29 July 2010 Keywords: Alzheimer; genome-wide; mitochondria; pathway; TOMM40 Genome-wide association studies are now abundant with hundreds of signal. Subsequently, each marker in the original SNP list with newly identified single loci being shown with a high degree of statistically significant evidence of association with a phenotype is probability to influence a variety of traits and diseases.1 However, evaluated to see (a) if it belongs to any proxy cluster and (b) if the for almost all tested traits only 1–2 genes are typically identified that marker itself or any marker in the cluster is located in a genic region.
    [Show full text]